Scott Rocklage is the current Managing Partner of 5AM Ventures and is based out of Waltham, MA office. He has years of experience in the healthcare management and is considered to be among the top executives in the industry who have made major contributions to the industry. As he had worked in both public and private healthcare companies in the country, he has the qualifications and the skills that one would need to be in a position that he is today and take the company to new heights.
5AM Ventures is a venture capital company established in 2002. The company offers seed and early stage investment solutions to its portfolio of clients ranging from biopharmaceutical, life sciences, medical technology, biopharma, biotechnology and also research industries. The company was able to secure a fund of $285 million. It previously raised $250 million 2013.
Scott joined 5AM Ventures in 2003 as a Venture Partner and was soon appointed as the Managing Director in 2004. Before joining 5AM Ventures, he was the CEO and Chairman of the Board of Cubist Pharmaceuticals Inc., from 1994 to 2003. He was also the President and Chief Executive Officer of Nycomed Salutar, a diagnostic imaging firm, from 1986 to 1989. During his long career in the healthcare industry, he had also held a number of positions in private pharmaceutical companies like Nycomed and Catalytica, Inc. He is currently the Executive Chairman of Relypsa, Inc, a biopharmaceutical company and the Chief Executive Officer of EPIRUS Biopharmaceuticals, Inc since 2016. He is also the board member of Pulmatrix and Cidara Therapeutics. He serves on the Board of Associates at the Whitehead Institute.
Scott has a strong educational background that made him successful in his career. He earned his BS degree in Chemistry from the University of California, Berkeley. Scott then went on get his Ph.D. in Chemistry from Massachusetts Institute of Technology under the guidance of Nobel Prize winner in Chemistry in 2005, Professor Richard R. Schrock. Over the years, he gained extensive experience and strategic leadership skills which, along with his scientific background, made him a pioneer in the field and a person to look up to in the industry. He is also known for being the co-inventor of about 30 patents and has more than 100 scientific publications to his name.
Scott Rocklage had led numerous teams over the years and raised more than $500 million which includes the one for Cubist Pharmaceuticals initial public offering and many more financing plans. The founders of 5AM Ventures were happy to make Scott a part of their company because of the vast experience that he brings to the company along with him. Scott had also known the founders for over 15 years and was happy to take on the opportunity when he was asked to join them.